STAT Plus: Experts parse Biogen’s Alzheimer’s data: Does the treatment work, or is it a mirage?
Beyond the grabby headlines, punchy tweets, and stock market bounces, Biogen’s surprise resuscitation of a once-doomed treatment for Alzheimer’s disease drew a hefty dose of caution — and even some skepticism.
The basis for Biogen’s decision was a re-analysis of data from late-stage studies of its drug, aducanumab. Those data, the company said, showed the treatment reduced the rate of patients’ cognitive decline.
Continue to STAT Plus to read the full story…
